# Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

> **NCT03206060** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 130 (estimated)

## Conditions studied

- Pheochromocytoma
- Paraganglioma
- Neuroendocrine Tumors
- Neuroendocrine Neoplasms

## Interventions

- **DRUG:** Lu-177-DOTATATE
- **DRUG:** Ga-68-DOTATATE

## Key facts

- **NCT ID:** NCT03206060
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-10
- **Primary completion:** 2030-01-01
- **Final completion:** 2033-01-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206060, "Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03206060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*